Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Gains from Sales and Divestitures (2022 - 2024)

Historic Gains from Sales and Divestitures for Lucid Diagnostics (LUCD) over the last 3 years, with Q4 2024 value amounting to $26912.0.

  • Lucid Diagnostics' Gains from Sales and Divestitures fell 9114.68% to $26912.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $26912.0, marking a year-over-year decrease of 9114.68%. This contributed to the annual value of $26912.0 for FY2024, which is 9114.68% down from last year.
  • According to the latest figures from Q4 2024, Lucid Diagnostics' Gains from Sales and Divestitures is $26912.0, which was down 9114.68% from $26912.0 recorded in Q3 2024.
  • Lucid Diagnostics' Gains from Sales and Divestitures' 5-year high stood at $303980.0 during Q3 2023, with a 5-year trough of $26912.0 in Q1 2024.
  • For the 3-year period, Lucid Diagnostics' Gains from Sales and Divestitures averaged around $149288.8, with its median value being $169320.0 (2022).
  • In the last 5 years, Lucid Diagnostics' Gains from Sales and Divestitures skyrocketed by 7952.99% in 2023 and then tumbled by 9114.68% in 2024.
  • Over the past 3 years, Lucid Diagnostics' Gains from Sales and Divestitures (Quarter) stood at $169320.0 in 2022, then surged by 79.53% to $303980.0 in 2023, then crashed by 91.15% to $26912.0 in 2024.
  • Its Gains from Sales and Divestitures was $26912.0 in Q4 2024, compared to $26912.0 in Q3 2024 and $26912.0 in Q2 2024.